Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients?

Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients?

The increasing diffusion of genetic analysis regarding the pathogenetic variants (PVs) of genes involved in DNA Damage Repair (DDR) mechanisms and the development of Poly ADP ribose polymerase (PARP) inhibitors (PARPis) led to the first valid precision medicine option tailored toward metastatic pros...

Full description

Bibliographic Details
Main Authors: Alessandro Sciarra, Valerio Santarelli, Lorenzo Santodirocco, Marco Frisenda, Stefano Salciccia, Paolo Casale, Flavio Forte, Gianna Mariotti, Martina Moriconi, Susanna Cattarino, Beatrice Sciarra, Giulio Bevilacqua, Alessandro Gentilucci
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Current Oncology
Subjects:
prostate cancer
PARP inhibitors
DDR gene
CRPC
Online Access:https://www.mdpi.com/1718-7729/30/9/584

Internet

https://www.mdpi.com/1718-7729/30/9/584

Similar Items